MFA
SLS icon

Millington Financial Advisors’s SELLAS Life Sciences SLS Stock Holding History

Millington Financial Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Hold
25,000
– – 0.13% 95
2026
Q1 		$122K Hold
25,000
– – 0.05% 115
2025
Q4 		$93.3K Buy
+25,000
New +$48.6K 0.04% 115

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millington Financial Advisors's SLS Position: Q2 2026 in Review

Millington Financial Advisors held its SELLAS Life Sciences (SLS) position steady in Q2 2026 at 25,000 shares worth $330K. The position accounts for 0.13% of the portfolio, ranked #95.

Millington Financial Advisors first reported a position in SLS in Q4 2025 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Millington Financial Advisors held 25,000 shares of SELLAS Life Sciences worth $330K as of Q2 2026.
  • Millington Financial Advisors left its SELLAS Life Sciences share count unchanged in Q2 2026.
  • SELLAS Life Sciences made up 0.13% of Millington Financial Advisors's portfolio in Q2 2026, its #95 holding.
  • Millington Financial Advisors first reported a position in SELLAS Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 193 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Millington Financial Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.